Epilepsy Drug of Lupin Gets US FDA Approval

HEALTHCARE

The pharmaceutical company ‘Lupin’ said that, the company has now received an approval from the Food and Drug Administration (FDA) of the United States for the Vigabatrin for the oral solution USP, and the approved ANDA (abbreviated new drug application) has been a generic equivalent of the Sabril for the oral solution of the company known as Lundbeck Pharmaceuticals, LLC.

The drug producing company said that, the product is going to be manufactured at the facility of the company ‘Lupin’ in the state of Goa, India, and the Vigabatrin has been a medication that is used for the purpose of treating the epilepsy.

Vigabatrin for the oral solution USP had now estimated the annual sales of 275 million dollars across the United States, and Lupin has been a transnational pharmaceutical company, and the company has also been developing and commercializing a wide range of the generic and branded formulations, along with the biotechnology products along with the Application Programming Interfaces (API) in more than 100 markets in the countries including South Africa, India, the United States and also across the Asia Pacific regions, Latin America, Middle-East and the European regions.

READ  US CDC Awards $215-Million As Part Of Revival Of Cancer Moonshot Initiative

The company has also consolidated a net profit that has been increased to 24.27 percent on an increase of 3.57 percent in the total revenue from the operations in the third quarter of the financial year 2022 over the third quarter of 2021.